Personal Info

E-mail: Paresh.vyas(at)imm.ox.ac.uk
Tel: 01865 222489
Web Link: http://www.imm.ox.ac.uk/wimm-research/molhaem/paresh-vyas

Academic Background:

Professor Vyas studied medicine at the University of Cambridge then University of Oxford, in the UK. After completing his general medical training in London, he did his PhD studying the control of gene regulation with Professor Doug Higgs and Professor Sir David Weatherall at the MRC Molecular Haematology Unit, John Radcliffe Hospital Oxford. He then completed his specialist training in Haematology at the Department of Haematology, Royal Free Hospital London under Professors AV Hoffbrand Grant Prentice. After this he spent three years with Professor Stuart Orkin at the Department of Haematology at Children’s Hospital Harvard University, where he developed his long-term interest in understanding the molecular basis of haematological disease. For the last 13 years he has been working as a Consultant Haematologist with a clinical practice in myeloid disorders (especially Acute Myeloid Leukaemia) at the Oxford University Hospital and running a research laboratory in the MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford. His research interests include understanding the haematological defect in MDS and AML, in adults and children with Down Syndrome. He was made Professor of Haematology 2 years ago.

Teaching Interests:

Undergraduate:
St Anne’s Medical student teaching

Graduate:
I help organise the Haematology teaching for the Pathology Course
I teach final year St Anne’s students
I mentor young doctors in training

Research Interests:

Molecular and cellular mechanisms that control normal blood cell production and understanding how these mechanisms are corrupted in Acute Leukaemia.

Awards:

2011 - Theme leader Oxford BRC Blood Theme.
2010 - Member of DoH UK Strategic Stem Cell Forum.

Grants:

2012 - MRC Molecular Haematology Unit Quinquennial Programme Award.
2011- CRUK Programme Grant2010 - MRC Disease Team Award.

Selected Publications:

• Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Woll P, Mead A, Alford KA, Rout R, Chaudhury S, Gilkes A, Knapper S, Soneji S, Beldjord K, Begum S, Rose S, Geddes N, Griffiths M, Standen G, Sternberg A, Cavenagh J, Hunter H, Bowen D, Killick S, Robinson L, Price A, Macintyre E, Virgo P, Burnett A, Craddock C, Enver T, Jacobsen SEW, Porcher C and Vyas P. Co-existence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia. Cancer Cell 19 p138-52 (2011)
• Alford K, Reinhardt K, Garnett C, Norton A, Böhmer K, von Neuhoff C, Kolenova A, Klusmann JH, Roberts I, Hasle H, Reinhardt D and Vyas P. Analysis of GATA1 mutations in Down Syndrome Transient Myeloproliferative Disorder and Myeloid leukemia. Blood 118: p.2222-38. (2011)
• O. Tunstall-Pedoe, A. Roy, A. Karadimitris, J. de la Fuente, N.M. Fisk, P. Bennett, P. Vyas and I. Roberts, ‘Perturbation of fetal hemopoiesis in Down syndrome: expansion of the MEP compartment precedes acquisition of GATA1 mutations’, Blood 112, 4507–11 (2008)
• I. Hamlett, J. Draper, J. Strouboulis, F. Iborra, C. Porcher and P. Vyas, ‘Characterisation of megakaryocyte GATA1-interacting proteins: the co-repressor ETO2 and GATA1 interact to regulate terminal megakaryocyte maturation’, Blood 112, 2738–49 (2008)
• B. Guyot, K. Murai, Y. Fujiwara, V. Garduno, N. Dear, S.H. Orkin, C. Porcher and P. Vyas, ‘Characterisation of a megakaryocyte-specific enhancer of the key haematopoietic transcription factor GATA1’, Journal of Biological Chemistry 281, 13733–42 (2006)
• C. Kuhl, A. Atzberger, B. Nieswandt, C. Porcher and P. Vyas, ‘GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1’, Molecular Cellular Biology 25, 8592–606 (2005)
• A. Sternberg, S. Killick, T. Littlewood, C. Hatton, A. Peniket, T. Seidl, S. Soneji, J. Leach, D. Bowen, C. Chapman, G. Standen, E. Massey, L. Robinson, B. Vadher, R. Kaczmarski, K. Clipsham, A. Carr and P. Vyas, ‘Evidence for reduced B-cell progenitors in early (low risk) myelodysplastic syndrome’, Blood 106, 2982–91 (2005)
• N.P. Rodrigues, R. Forkert, V. Janzen, D.M. Dombkowski, A.S. Boyd, S.H. Orkin, T. Enver, P. Vyas* and D.T. Scadden*, ‘Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem cell homeostasis’, Blood 106, 477–84 (2005). *Joint senior authors
• V. Valverde-Garduno, B. Guyot, E. Anguita, I. Hamlet, C. Porcher and P. Vyas, ‘Unexpected differences in the physical and functional organisation of the human and mouse GATA1 loci: implications for cis-element identification’, Blood 104, 3106–116 (2004)
• P. Vyas, K. Ault, C.W. Jackson, S.H. Orkin and R. Shivdasani, ‘Consequences of GATA-1 deficiency in megakaryocytes’, Blood 93, 2867–75 (1999)
• P. Vyas, F.A. Norris, J. Raji, P. Majerus, S.H. Orkin, ‘Inositol 4-Phosphatase type I regulates cell grow downstream of transcription factor GATA-1’, PNAS 97, 13969–701 (2000)
• P. Vyas, M.A. Mcdevitt, A.B. Cantor, S. Katz, Y. Fujiwara and S.H. Orkin, ‘Different sequences are required for expression in erythroid and magakaryocytic cells within a regulatory element upstream of the GATA-1 gene’, Development 126, 2799–811 (1999)
• P. Vyas, K. Ault, C.W. Jackson, S.H. Orkin and R. Shivdasani, ‘Consequences of GATA-1 deficiency in megakaryocytes’, Blood 93, 2867–75 (1999)
• P. Vyas, M.A. Vickers, D. Simmons, C.F. Craddock, H. Ayyub and D.R. Higgs, ‘Cis-acting sequences regulating expression of the human globin cluster lie within constitutively open chromatin’, Cell 69, 781–93 (1992)